JP2009510046A - インターロイキン−１３抗体組成物 - Google Patents

インターロイキン−１３抗体組成物 Download PDF

Info

Publication number
JP2009510046A
JP2009510046A JP2008532878A JP2008532878A JP2009510046A JP 2009510046 A JP2009510046 A JP 2009510046A JP 2008532878 A JP2008532878 A JP 2008532878A JP 2008532878 A JP2008532878 A JP 2008532878A JP 2009510046 A JP2009510046 A JP 2009510046A
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
composition according
sodium
buffered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510046A5 (enExample
Inventor
ブレンダン・コーミック・フィッシュ
ジャネット・エリザベス・ラングストーン
カレン・バニスター
クレア・ルイーズ・ホープ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37434894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009510046(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0519923.7A external-priority patent/GB0519923D0/en
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2009510046A publication Critical patent/JP2009510046A/ja
Publication of JP2009510046A5 publication Critical patent/JP2009510046A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2008532878A 2005-09-30 2006-09-29 インターロイキン−１３抗体組成物 Pending JP2009510046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72197405P 2005-09-30 2005-09-30
GBGB0519923.7A GB0519923D0 (en) 2005-09-30 2005-09-30 Interleukin-13 antibody composition
PCT/GB2006/003650 WO2007036745A2 (en) 2005-09-30 2006-09-29 Interleukin-13 antibody composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013212846A Division JP5820450B2 (ja) 2005-09-30 2013-10-10 インターロイキン−１３抗体組成物

Publications (2)

Publication Number Publication Date
JP2009510046A true JP2009510046A (ja) 2009-03-12
JP2009510046A5 JP2009510046A5 (enExample) 2009-07-09

Family

ID=37434894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008532878A Pending JP2009510046A (ja) 2005-09-30 2006-09-29 インターロイキン−１３抗体組成物
JP2013212846A Active JP5820450B2 (ja) 2005-09-30 2013-10-10 インターロイキン−１３抗体組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013212846A Active JP5820450B2 (ja) 2005-09-30 2013-10-10 インターロイキン−１３抗体組成物

Country Status (21)

Country Link
US (3) US20080248048A1 (enExample)
EP (1) EP1942939B2 (enExample)
JP (2) JP2009510046A (enExample)
KR (1) KR101363777B1 (enExample)
AU (1) AU2006296399B2 (enExample)
BE (1) BE2021C552I2 (enExample)
BR (1) BRPI0616359B8 (enExample)
CA (1) CA2623429C (enExample)
CY (2) CY1120874T1 (enExample)
FI (1) FIC20210042I1 (enExample)
FR (1) FR21C1055I2 (enExample)
GB (1) GB2430883B (enExample)
HU (1) HUS2100053I1 (enExample)
IL (3) IL189983A (enExample)
LT (1) LTC1942939I2 (enExample)
LU (1) LUC00239I2 (enExample)
NL (1) NL301143I2 (enExample)
NO (2) NO344859B1 (enExample)
PL (1) PL1942939T5 (enExample)
SI (1) SI1942939T2 (enExample)
WO (1) WO2007036745A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
JP2014520847A (ja) * 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
AU2008269086B2 (en) * 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
NZ601815A (en) 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
NZ599100A (en) 2009-10-20 2014-07-25 Abbvie Inc Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
AU2012332767C1 (en) 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
WO2013148232A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
JP6156962B2 (ja) 2014-02-27 2017-07-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム エキソソームを単離するための方法および組成物
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6247241B2 (ja) * 2015-02-27 2017-12-13 ノバルティス アーゲー 抗体処方
EP3271723A1 (en) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
TWI787203B (zh) 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
WO2020219943A1 (en) 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
EP4126943B1 (en) 2020-03-23 2026-04-22 MedImmune Limited Methods for treating atopic dermatitis and related disorders
CA3097453A1 (en) 2020-03-23 2021-09-23 Medimmune Limited Methods for treating atopic dermatitis and related disorders
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
KR20240046243A (ko) 2021-08-16 2024-04-08 메디뮨 엘엘씨 항-il-13 항체 제제
IL311027A (en) 2021-09-15 2024-04-01 Dermira Inc Il-13 inhibitors for the treatment of prurigo nodularis
EP4408885A1 (en) 2021-09-28 2024-08-07 MedImmune Limited Methods for treating atopic dermatitis and related disorders
CN122374333A (zh) 2023-12-14 2026-07-10 德米拉公司 用于治疗慢性鼻窦炎伴鼻息肉的il-13抗体
AU2024399620A1 (en) 2023-12-14 2026-05-14 Dermira, Inc. Il-13 antibodies for the treatment of perennial allergic rhinitis
TW202600591A (zh) 2024-03-01 2026-01-01 美商德米拉股份有限公司 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
WO2026086810A1 (zh) * 2024-10-22 2026-04-30 海南先声药业有限公司 抗il-13抗体及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500567A (ja) * 1991-03-29 1994-01-20 エルフ・サノフィ サイトカイン型の活性を有するタンパク質、およびこのタンパク質をコード化する組換えｄｎａ、形質転換細胞および微生物
JPH07267994A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造法
JPH0854391A (ja) * 1994-08-09 1996-02-27 Iatron Lab Inc ジフェニルエーテル化合物に特異的なモノクローナル抗体、ハイブリドーマ、及びジフェニルエーテル化合物の検出方法
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH11512753A (ja) * 1996-05-24 1999-11-02 グラクソ、グループ、リミテッド 濃縮抗体製剤
JP2000146973A (ja) * 1998-11-17 2000-05-26 Sekisui Chem Co Ltd Ｉｖ型コラーゲンの免疫測定法及び試薬
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2005007699A2 (en) * 2003-07-15 2005-01-27 Cambridge Antibody Technology Limited Human antibody molecules for il-13
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
US20050158316A1 (en) * 1997-06-13 2005-07-21 Genentech, Inc. Antibody formulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685919B1 (fr) * 1992-01-08 1994-04-08 Elf Sanofi Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees.
US5866154A (en) † 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
BR9708910A (pt) † 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
ID27417A (id) † 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
GB2361704C (en) † 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
EP1175931A1 (en) † 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
WO2003010512A2 (en) † 2001-07-23 2003-02-06 Accurate Polymers, Inc. High-speed, solid-liquid separation
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20040234499A1 (en) † 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
WO2004076485A1 (en) † 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
US20060257972A1 (en) † 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
MX361174B (es) † 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
CN1234725C (zh) † 2004-04-07 2006-01-04 陈志南 一种高效快速纯化制备片段抗体的方法
AR049390A1 (es) † 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
CA2577631A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
EP2652038A1 (en) † 2010-10-14 2013-10-23 Ticona GmbH Plasticized polyoxymethylene

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500567A (ja) * 1991-03-29 1994-01-20 エルフ・サノフィ サイトカイン型の活性を有するタンパク質、およびこのタンパク質をコード化する組換えｄｎａ、形質転換細胞および微生物
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH07267994A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造法
JPH0854391A (ja) * 1994-08-09 1996-02-27 Iatron Lab Inc ジフェニルエーテル化合物に特異的なモノクローナル抗体、ハイブリドーマ、及びジフェニルエーテル化合物の検出方法
JPH11512753A (ja) * 1996-05-24 1999-11-02 グラクソ、グループ、リミテッド 濃縮抗体製剤
US20050158316A1 (en) * 1997-06-13 2005-07-21 Genentech, Inc. Antibody formulation
JP2000146973A (ja) * 1998-11-17 2000-05-26 Sekisui Chem Co Ltd Ｉｖ型コラーゲンの免疫測定法及び試薬
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2005007699A2 (en) * 2003-07-15 2005-01-27 Cambridge Antibody Technology Limited Human antibody molecules for il-13

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
JP2014520847A (ja) * 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物

Also Published As

Publication number Publication date
IL230005A (en) 2016-05-31
US20080248048A1 (en) 2008-10-09
GB2430883A (en) 2007-04-11
FR21C1055I2 (fr) 2022-11-18
US9107945B2 (en) 2015-08-18
NL301143I1 (enExample) 2021-11-10
IL189983A (en) 2016-11-30
GB2430883B (en) 2008-03-19
US20160002327A1 (en) 2016-01-07
BRPI0616359B1 (pt) 2021-09-08
HUS2100053I1 (hu) 2021-12-28
IL230005A0 (en) 2014-01-30
JP5820450B2 (ja) 2015-11-24
IL189983A0 (en) 2008-08-07
AU2006296399B2 (en) 2011-01-20
EP1942939B1 (en) 2018-05-30
WO2007036745A3 (en) 2007-08-02
US10358488B2 (en) 2019-07-23
EP1942939A2 (en) 2008-07-16
FR21C1055I1 (enExample) 2021-12-24
CA2623429C (en) 2015-01-13
GB0619204D0 (en) 2006-11-08
FIC20210042I1 (fi) 2021-11-23
CY2021033I1 (el) 2022-03-24
BRPI0616359B8 (pt) 2022-08-30
BRPI0616359A2 (pt) 2011-06-14
JP2014040461A (ja) 2014-03-06
LTC1942939I2 (enExample) 2023-10-10
HK1210724A1 (en) 2016-05-06
LUC00239I2 (enExample) 2025-02-03
EP1942939B2 (en) 2021-07-07
CA2623429A1 (en) 2007-04-05
PL1942939T3 (pl) 2018-10-31
AU2006296399A1 (en) 2007-04-05
US20110086038A1 (en) 2011-04-14
NO344859B1 (no) 2020-06-02
AU2006296399A8 (en) 2008-07-17
SI1942939T2 (sl) 2021-11-30
SI1942939T1 (sl) 2018-10-30
NO2021050I1 (no) 2021-11-12
IL246674B (en) 2019-09-26
KR101363777B1 (ko) 2014-02-14
LTPA2021528I1 (enExample) 2021-12-27
CY1120874T1 (el) 2019-12-11
BE2021C552I2 (enExample) 2026-01-14
NO20081946L (no) 2008-06-27
KR20080054429A (ko) 2008-06-17
NL301143I2 (nl) 2022-02-10
PL1942939T5 (pl) 2021-10-11
WO2007036745A2 (en) 2007-04-05
IL246674A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
JP5820450B2 (ja) インターロイキン−１３抗体組成物
JP6007316B2 (ja) 抗体製剤
CN102202655B (zh) 基因工程抗IL-23p19抗体的冻干制剂
EP2473191B1 (en) Antibody coformulations
CA3200767A1 (en) Anti-tslp antibody pharmaceutical composition and use thereof
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
EP4151233A1 (en) Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof
JP6339578B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
CA3253236A1 (en) Bispecific binding proteins against alarmins and their uses
DK1942939T3 (en) Interleukin-13 antibody composition
HK1210724B (en) Interleukin-13 antibody composition
HK40120136A (en) Bispecific binding proteins against alarmins and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131010